Filters
Term Search
You can select from the dropdown list OR enter your own terms to refine the search.
Last Updated: 10/31/2025
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 191 publications
IDeate-Lung02: a Phase 3 study of second-line ifinatamab deruxtecan in patients with relapsed small cell lung cancer.
Journal: Future oncology (London, England)
Published: October 07, 2025
Small cell lung cancer (SCLC): At the door of targeted therapies.
Journal: Biomolecules & biomedicine
Published: August 28, 2025
Therapeutic Effects of Lurbinectedin in PARP Inhibitor-Resistant High-Grade Serous Ovarian Cancer Using Patient-Derived Cell Lines and Organoid Models.
Journal: International journal of molecular sciences
Published: August 07, 2025
The DNA Minor Groove Binders Trabectedin and Lurbinectedin Are Potent Antitumor Agents in Human Intrahepatic Cholangiocarcinoma.
Journal: International journal of molecular sciences
Published: July 18, 2025
Cost-effectiveness analysis of lurbinectedin plus atezolizumab as first-line treatment for extensive-stage small-cell lung cancer.
Journal: Frontiers in immunology
Published: July 03, 2025
Aligning organ-specific toxicities with formulation strategies: a rational design approach to chemotherapy optimization.
Journal: International journal of pharmaceutics
Published: July 02, 2025
IMforte: A new starting point and new challenges.
Journal: Med (New York, N.Y.)
Published: June 24, 2025
Adding lurbinectedin to maintenance therapy improves outcomes in ES-SCLC.
Journal: Nature reviews. Clinical oncology
Published: June 12, 2025
Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy.
Journal: The New England journal of medicine
Published: June 02, 2025
Second-line treatment strategies and clinical outcomes after progression on chemoimmunotherapy in extensive-stage small-cell lung cancer.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: June 01, 2025
Last Updated: 10/31/2025